EUVIMEDEUVIMED entdecken
Crossref

Development of the novel formulations of perospirone for the treatment of schizophrenia

Zijun Zhang, Famin Ke, Jili Wu, Xiyao Li, Xin Chen, Lanxing Zhang, Pei Jing, Zerong Liu, Zhongbing Liu, Ruilin Lu, Shihua Fu, Meiling Zhou und 3 weitere

Drug Delivery and Translational Research · 2025

DOI: 10.1007/s13346-024-01730-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Zijun Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Electrophysiology, Ministry of Education, School of Pharmacy, Southwest Medical University, 646000, Luzhou, Sichuan, China. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents, Isoindoles, Thiazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: the Sichuan Science and Technology Program, Chunhui Project Foundation of the Education Department of China, the Science and Technology Strategic Cooperation Project of Suining First Peoples Hospital and Southwest Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schizophrenia is a severe mental illness. Its clinical features include positive symptoms (hallucinations, delusions, thought disorders), negative symptoms (avolition, anhedonia, poverty of thought, social withdrawal), and cognitive dysfunction. A large number of antipsychotic drugs with traditional dosage forms are available to mitigate the symptoms of schizophrenia but the duration of action is commonly short, often requiring frequent administration. The perospirone hydrochloride hydrate (PER), as a second-generation antipsychotic drug, shows therapeutic effects on both positive and negative symptoms of schizophrenia, with less impact on cognitive function. However, it suffers from a short half-life, fluctuating blood concentration, instability in the circulating leading to peak-trough fluctuations, and poor patient compliance due to the required frequent administration. Based on the hydrophilic matrix, we developed novel formulations of PER, including the extended-release and the controlled-release tablets of PER. The resulting formulations delayed the drug release and prolonged the persistence of PER, leading to an extended half-life and reduced fluctuations in blood concentration with stable therapeutic levels and an improved absorption with higher bioavailability, thus reducing dosing frequency. These oral extended-release and controlled-release tablets promise to alleviate patients' medication discomfort and provide long-term sustained drug release. They would provide a platform with broad prospects for the clinical treatment of schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaAntipsychotic AgentsIsoindolesThiazolesHumansDelayed-Action PreparationsHalf-LifeTabletsAnimalsBiological AvailabilityDrug Liberation

Stichwörter der Autor:innen

Controlled-release tabletExtended-release tabletPerospirone hydrochloride hydratePharmacokinetic profileSchizophrenia

Substanzen

Antipsychotic AgentsperospironeDelayed-Action PreparationsIsoindolesTabletsThiazoles

Autor:innen und Institutionen

  • Key Laboratory of Medical Electrophysiology, Ministry of Education, School of Pharmacy, Southwest Medical University, 646000, Luzhou, Sichuan, China.
  • Deyang Hospital, the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 618000, Deyang, Sichuan, China.
  • Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, 646000, Luzhou, Sichuan, China.
  • Central Nervous System Drug Key Laboratory of Sichuan Province, 646000, Luzhou, Sichuan, China.
  • Suining First People's Hospital, 629099, Suining, Sichuan, China.
  • Xuyongxian People's Hospital, 646499, Xuyong, Luzhou, Sichuan, China.

ORCID-Profile: Zhirong Zhong

Förderung

  • the Sichuan Science and Technology Program
  • Chunhui Project Foundation of the Education Department of China
  • the Science and Technology Strategic Cooperation Project of Suining First Peoples Hospital and Southwest Medical University
  • the Science and Technology Strategic Cooperation Project of Xuyongxian People's Hospital and Southwest Medical University
  • the Central Nervous System Drug Key Laboratory of Sichuan Province
  • the Science and Technology Strategic Cooperation Project of Xuyongxian People’s Hospital and Southwest Medical University

Zitieren

APA

Zhang, Z., Ke, F., Wu, J., Li, X., Chen, X., Zhang, L., Jing, P., Liu, Z., Liu, Z., Lu, R., Fu, S., Zhou, M., Lin, Y., Sun, X., & Zhong, Z. (2025). Development of the novel formulations of perospirone for the treatment of schizophrenia. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01730-7

Vancouver

Zhang Z, Ke F, Wu J, Li X, Chen X, Zhang L, et al. Development of the novel formulations of perospirone for the treatment of schizophrenia. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-024-01730-7

BibTeX
@article{Zhang2025,
  author = {Zhang, Zijun and Ke, Famin and Wu, Jili and Li, Xiyao and Chen, Xin and Zhang, Lanxing and Jing, Pei and Liu, Zerong and Liu, Zhongbing and Lu, Ruilin and Fu, Shihua and Zhou, Meiling and Lin, Yan and Sun, Xiaoduan and Zhong, Zhirong},
  title = {Development of the novel formulations of perospirone for the treatment of schizophrenia},
  journal = {Drug Delivery and Translational Research},
  year = {2025},
  doi = {10.1007/s13346-024-01730-7}
}
Kostenlos starten →